Effective chelation of iron in β thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one

British Medical Journal (Clinical research ed.)

Volumn 295, Issue 6612, 1987, Pages 1509-1512

  Kontoghiorghes, George J ^a   Aldouri, Maadh A ^a   Hoffbrand, A Victor ^a   Barr, Joan ^a   Wonke, Beatrix ^a   Kourouclaris, Theo ^a   Sheppard, Lyndon ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; DEFERIPRONE; DEFEROXAMINE; IRON;

BETA THALASSEMIA; CLINICAL ARTICLE; DRUG THERAPY; HUMAN; HUMAN EXPERIMENT; IRON CHELATION; MYELODYSPLASIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; URINE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ASCORBIC ACID; CLINICAL TRIALS; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MALE; MIDDLE AGED; NEURAL TUBE DEFECTS; PYRIDONES; THALASSEMIA;

EID: 0023489829     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.295.6612.1509     Document Type: Article

References (29)

1. Propper R. D. Cooper B, Rufo R. R., et al. Continuous subcutaneous administration of desferrioxa-mine in patients with iron overload. N Engl J Med 1977;297:418-23.
2. Hussain MAM, Flynn D. M., Green N, Hussein S, Hoffbrand AV. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 1976;ii:1278-80.
3. Oliviery N. F. Buncic R. J. Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. N Engl J Med 1986;314:869-73.
4. Callender S. T. Weatherall DJ. Iron chelation with oral desferrioxamine. Lancet 1980;i:689.
5. Kontoghiorghes G. J. Marcus R. E. Huehns ER. Desferrioxamine suppositories. Lancet 1983;ii:454.
6. Peterson C. M. Graziano J. H. Grady R. W., et al. Chelation studies with 2,3-dihydroxybenzoic acid in patients with β thalassaemia major. Br J Haematol 1976;33:447-85.
7. Grady R. W. Peterson C. M. Jones R. L., et al. Rhodotorulic acid investigation of its potential as an iron chelating drug. J Pharmacol Exp Ther 1979;209:342-8.
8. Cerami A, Grady R. W., Peterson C. M. Bhargava KK. The status of new iron chelators. Ann NY Acad Sci 1980;344:415-35.
9. Pippard M. J. Jackson M. J. Hoffman K, Petrou M, Modell CB. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 1986;36:466-72.
10. Kontoghiorghes G. J. The effect of 2,4,dihydroxypyridine-N-oxide, a new orally active iron chelator, on iron excretion in mice. Clin Chim Acta 1987;167:137-41.
11. Hoy T, Humphries J, Jacobs A, Williams A, Ponka P. Effective iron chelation following oral administration of an isoniazid-pyridoxalhydrazone. Br J Haematol 1979;43:443-9.
12. Bergeron R. J. McGovern K. A. Channing M. A., Burton PS. Synthesis of N4-acylated N1, N8-bis(acyl) spermidines: an approach to the synthesis of siderophores. Journal of Organic Chemistry 1980;45:1589-92.
13. Peter H. H. Eisenchelierung. Schweiz Med Wochensckr 1983;113:1428-33.
14. Hershko C, Grady R. W., Link G. Phenolic ethylenediamine derivatives: a study of orally effective chelators. J Lab Clin Med 1984;103:337-46.
15. Kontoghiorghes G. J. The design of orally active iron chelators for the treatment of thalassaemia. Colchester, Essex: University of Essex, 1982. 243 pp (Thesis.) (British Library microfilm D66194/86.)
16. Kontoghiorghes G. J. Sheppard L. Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorganica Chimica Acta 1987;136:L11-2.
17. Kontoghiorghes G. J. Structure/iron binding activity of l-hydroxypyrid-2-one chelators intended for clinical use. Inorganica Chimica Acta 1987;135:145-50.
18. Kontoghiorghes G. J. The study of iron mobilisation from transferrin using a-ketohydroxy heteroaromatic chelators. Biochimica etBiophysica Acta 1986;869:141-6.
19. Kontoghiorghes G. J. Iron mobilisation from lactoferrin by chelators at physiological pH. Biochimica et Biophysica Acta 1986;882:267-70.
20. Kontoghiorghes G. J. Iron mobilisation from ferritin using α-oxohydroxy-heteroaromatic chelators. Biochem J 1986;233:299-302.
21. Kontoghiorghes G. J. Chambers S, Hoffbrand AV. Comparative iron mobilisation from haemo-siderin, ferritin and iron (III) precipitates by chelators. Biochem J 1987;241:87-92.
22. KontjDghiorghes G. J. New orally active iron chelators. Lancet 1985;i:817.
23. Kontoghiorghes G. J. Hoffbrand AV. Orally active α-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits. Br J Haematol 1986;62:607-13.
24. Kontoghiorghes G. J. Aldouri M, Sheppard L, Hoffbrand AV. l.,2-Dimethy1-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;i: 1294-5.
25. Pippard M. J. Callender S. T. Finch CA. Ferrioxamine excretion in iron loaded man. Blood 1987;60:288-94.
26. Kontoghiorghes G. J. Dose response studies using desferrioxamine and orally active chelators in a mouse model. Scand J Haematol 1986;37:63-70.
27. Kontoghiorghes G. J. Orally active a-ketohydroxy pyridine iron chelators: studies in mice. Mol Pharmacol 1986;37:62-70.
28. Kontoghiorghes G. J. Iron chelation in biochemistry and medicine. In: Rice-Evans C, ed. Free radicals oxidant stress and drug action. London: Richelieu Press, 1987:277-303.
29. Kontoghiorghes G. J. Sheppard L, Chambers S. New synthetic approach and iron chelating studies of 1 -alky1-2-methy1-3-hydroxypyrid-4-ones. Arzneimittelforsch 1987;37:1099-1102.